Pembrolizumab, an immune checkpoint inhibitor, has been approved by the US Food and Drug Administration for the treatment of ...

A grandad with advanced lung cancer which often leaves patients dead within four months has become free of the disease after ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

A new research paper was published in Volume 16 of Oncotarget on June 10, 2025, titled "Exceptional responders to ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to advance at a resilient ...

Atezolizumab did not confer any benefits when added to SBRT in a phase 3 trial of patients with inoperable, early-stage NSCLC.

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Cancer plasticity allows tumor cells to change their identity, evade therapies, and adapt to environmental pressures, contributing to treatment resistance and metastasis. New research is targeting ...

Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, ...